RxDoctor Payments Data

Savannah King

Nurse Practitioner · Lebanon, KYNPI 1437614120

Payments from drug & device makers

$6,143in general payments, 2019–2025

Across 396 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$853
  • Novartis$758
  • AstraZeneca$604
  • Merck$560
  • Esperion Therapeutics, Inc.$351
  • Pfizer$325
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$6,143100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,143 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$107,283
Medicare patients
961
Services billed
1,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban838$783,420
XareltoRivaroxaban156$159,349
EntrestoSacubitril/Valsartan136$136,990
FarxigaDapagliflozin Propanediol140$132,484
CamzyosMavacamten13$108,422
BrilintaTicagrelor85$76,760
Repatha SureclickEvolocumab97$66,129
JardianceEmpagliflozin47$49,604
VascepaIcosapent Ethyl34$13,707
Metoprolol Succinate759$9,037
Icosapent Ethyl14$7,718
Diltiazem 24hr Er (Cd)Diltiazem Hcl192$6,044
NexletolBempedoic Acid11$5,816
Pitavastatin Calcium25$5,176
Atorvastatin Calcium622$4,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$325$783,420838 claims
AstraZenecaFarxiga, Brilinta$604$209,243225 claims
Johnson & JohnsonXarelto$317$159,349156 claims
NovartisEntresto$758$136,990136 claims
E.r. Squibb & Sons, L.L.C.Camzyos$188$108,42213 claims
Boehringer IngelheimJardiance$106$49,60447 claims
Esperion Therapeutics, Inc.Nexletol$351$5,81611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Lebanon

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →